Updates
** Shares of drug developer Summit Therapeutics SMMT.O fall 12.6% to $19.33
** Company reports fourth-quarter net loss of $61.1 million, vs analysts' estimate of a loss of $60.54 million, as per data compiled by LSEG
** Brokerage Truist Securities analysts say: "from what we understand with our buyside discussions is that there were some expectations for deal announcements, perhaps with more economic scope than what was disclosed between SMMT & Pfizer"
** Brokerage added: "We think changes to SMMT's participation in investor conferences may not be a good indicator of potential deal announcements"
** SMMT says it is collaborating with Pfizer PFE.N to study its experimental drug ivonescimab in combination with several of Pfizer's targeted cancer therapies, called antibody drug conjugates (ADCs), across different types of tumors
** Stock has risen 5x in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。